Urinary Protein Excretion – Even in the Normal Range – Raises Diabetics’ Heart Risks

Released: 8/24/2012 9:00 AM EDT
Embargo expired: 8/30/2012 5:00 PM EDT
Source Newsroom: American Society of Nephrology (ASN)
Contact Information

Available for logged-in reporters only

Citations Journal of the American Society of Nephrology (doi: 10.1681/ASN.2012030252)

Many patients may benefit from cardioprotective medications

Highlights
• For patients with type 2 diabetes, any degree of measurable urinary protein excretion—even in what is considered the normal range—increases their risk of experiencing heart problems.
• Many patients with type 2 diabetes may benefit from cardioprotective medications.

More than 300 million people worldwide have type 2 diabetes.

Newswise — Washington, DC (August 30, 2012) — In individuals with type 2 diabetes, any degree of measurable urinary protein excretion—even in what is considered the normal range—increases their risk of experiencing heart problems, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN). The findings could help identify patients who should be treated with cardioprotective medications.

Some patients with type 2 diabetes experience kidney problems that cause them to excrete increased amounts of the protein albumin in their urine, a condition called albuminuria. These patients have a considerably higher risk of developing heart problems—such as heart attacks, strokes, and heart failure—than other diabetic patients and people in the general population, who are “normoalbuminuric,” with urinary albumin excretion levels of less than 20 μg/min.

Investigators have wondered if any level of albumin excretion—for example at a level that is the upper range of what is considered normal—might increase a diabetic patient’s risk of developing heart problems. “It would be important to know whether there is a level for albuminuria that differentiates individuals in need of cardioprotective intervention from those with a low risk,” said Giuseppe Remuzzi, MD, FRCP, (Mario Negri Institute for Pharmacological Research and Ospedali Riuniti, in Bergamo, Italy). “This is a major health issue since patients with normoalbuminuria account for at least 90% of the diabetic population,” he added.

Through an extension of a clinical trial originally designed for other purposes, Dr. Remuzzi, along with Piero Ruggenenti, MD, Esteban Porrini MD (Mario Negri Institute for Pharmacological Research), and others, evaluated the relationship between albumin excretion levels and heart problems in 1,208 normoalbuminuric patients with type 2 diabetes who were followed for an average of 9.2 years.

The researchers found that any degree of measurable albumin excretion bore significant heart risks:
• For each 1 μg/min in albumin excretion at the start of the study, there was a progressive incremental risk of experiencing heart problems during follow-up.
• Even albuminuria of 1-2 μg/min significantly associated with increased risk compared with albuminuria <1 μg/min.

When the investigators looked only at the subgroup of patients who took antihypertensive drugs called ACE inhibitors from the start of the study and throughout the follow-up period, they found no link between albumin excretion levels and heart risks. This suggests that ACE inhibitors have heart-protective properties that may benefit diabetic patients with albuminuria and normoalbuminuria alike. Future clinical trials are needed to identify levels of albumin excretion above which such cardioprotective therapy is beneficial.

Study co-authors include Nicola Motterlini StatSciD, Annalisa Perna, StatSciD, Aneliya Parvanova Ilieva MD, Ilian Petrov Iliev MD, Alessandro Roberto Dodesini MD, Roberto Trevisan MD, Antonio Bossi MD, Giuseppe Sampietro MD, Enrica Capitoni RN, Flavio Gaspari PhD, Nadia Rubis RN, Bogdan Ene-Iordache EngD.

Disclosures: The authors reported no financial disclosures.

The article, entitled “Measurable Urinary Albumin Predicts Cardiovascular Risk Among Normoalbuminuric Type 2 Diabetics,” will appear online at http://jasn.asnjournals.org/ on August 30, 2012, doi: 10.1681/ASN.2012030252.


The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

# # #


Comment/Share